Primary drug resistance in South Africa: data from 10 years of surveys.

HIV-1 transmitted drug resistance (TDR) could reverse the gains of antiretroviral rollout. To ensure that current first-line therapies remain effective, TDR levels in recently infected treatment-naive patients need to be monitored. A literature review and data mining exercise was carried out to determine the temporal trends in TDR in South Africa. In addition, 72 sequences from seroconvertors identified from Africa Centre's 2010 HIV surveillance round were also examined for TDR. Publicly available data on TDR were retrieved from GenBank, curated in RegaDB, and analyzed using the Calibrated Population Resistance Program. There was no evidence of TDR from the 2010 rural KwaZulu Natal samples. Ten datasets with a total of 1618 sequences collected between 2000 and 2010 were pooled to provide a temporal analysis of TDR. The year with the highest TDR rate was 2002 [6.67%, 95% confidence interval (CI): 3.09-13.79%; n=6/90]. After 2002, TDR levels returned to <5% (WHO low-level threshold) and showed no statistically significant increase in the interval between 2002 and 2010. The most common mutations were associated with NNRTI resistance, K103N, followed by Y181C and Y188C/L. Five sequences had multiple resistance mutations associated with NNRTI resistance. There is no evidence of TDR in rural KwaZulu-Natal. TDR levels in South Africa have remained low following a downward trend since 2003. Continuous vigilance in monitoring of TDR is needed as more patients are initiated and maintained onto antiretroviral therapy.

[1]  O. Onwujekwe,et al.  Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. , 2009, Health policy and planning.

[2]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[3]  M. Segal,et al.  Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.

[4]  D. Heckerman,et al.  Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point , 2008, Journal of Virology.

[5]  L. Morris,et al.  Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. , 2006, AIDS research and human retroviruses.

[6]  D. Pillay,et al.  Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom , 2001, BMJ : British Medical Journal.

[7]  W. Heneine,et al.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.

[8]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[9]  D. Bennett,et al.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.

[10]  D. Bennett,et al.  A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings , 2008, Antiviral therapy.

[11]  A. Kamali,et al.  Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. , 2011, AIDS research and human retroviruses.

[12]  H. Coovadia,et al.  Molecular characteristics of HIV-1 Subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies , 2003 .

[13]  Tulio de Oliveira,et al.  A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences , 2009, Nucleic Acids Res..

[14]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[15]  D. Katzenstein,et al.  Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa , 2011, PloS one.

[16]  T. Bärnighausen,et al.  Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. , 2009, AIDS research and human retroviruses.

[17]  C. Rouzioux,et al.  HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.

[18]  R. Kaiser,et al.  Trends of prevalence of primary HIV drug resistance in Germany. , 2007, The Journal of antimicrobial chemotherapy.

[19]  W. Preiser,et al.  Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. , 2008, AIDS research and human retroviruses.

[20]  L. Morris,et al.  HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. , 2002, AIDS research and human retroviruses.

[21]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[22]  M. Zvelebil,et al.  A model of directional selection applied to the evolution of drug resistance in HIV-1. , 2007, Molecular biology and evolution.

[23]  D. Bennett,et al.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites , 2008, Antiviral therapy.

[24]  T. Bärnighausen,et al.  Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. , 2009, International journal of epidemiology.

[25]  J. Mellors,et al.  Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Antinori,et al.  Treatment‐Related Factors and Highly Active Antiretroviral Therapy Adherence , 2002, Journal of acquired immune deficiency syndromes.

[27]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[28]  T. Corrah,et al.  Antiretroviral therapy in Africa , 2004, BMJ : British Medical Journal.

[29]  Deenan Pillay,et al.  Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe , 2004, Antiviral therapy.

[30]  S. Hammer,et al.  Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission , 2006, AIDS.

[31]  L. Morris,et al.  Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. , 2005, AIDS research and human retroviruses.

[32]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[33]  D. Bennett,et al.  Darunavir: pharmacokinetics and drug interactions. , 2008 .

[34]  M. Newell,et al.  COHORT PROFILE Cohort Profile : Hlabisa HIV Treatment and Care Programme , 2010 .

[35]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[36]  O. Gascuel,et al.  A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. , 2003, Systematic biology.

[37]  J. Fisher,et al.  First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. , 2002, AIDS.

[38]  Till Bärnighausen,et al.  Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey , 2007, International journal of epidemiology.

[39]  P. Klenerman,et al.  Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa , 2009, Antiviral therapy.

[40]  L. Mofenson,et al.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.

[41]  Tulio de Oliveira,et al.  Public database for HIV drug resistance in southern Africa , 2010, Nature.

[42]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[43]  R. Byers,et al.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. , 2002, AIDS research and human retroviruses.

[44]  T. F. Rinke de Wit,et al.  HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia , 2010, Journal of acquired immune deficiency syndromes.

[45]  Kishor Mandaliya,et al.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.

[46]  W. Heneine,et al.  Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. , 2000, The Journal of infectious diseases.

[47]  Robert J. Gifford,et al.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance , 2009, Bioinform..

[48]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[49]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[50]  R. Parboosing,et al.  Resistance to antiretroviral drugs in newly diagnosed, young treatment‐naïve HIV‐positive pregnant women in the province of KwaZulu‐Natal, South Africa , 2011, Journal of medical virology.

[51]  T. Bärnighausen,et al.  High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study , 2008, AIDS.

[52]  J. Nelson,et al.  Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007 , 2008, Antiviral therapy.